Suppliers and packagers for EZETIMIBE

EZETIMIBE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Accord Hlthcare	EZETIMIBE	ezetimibe	TABLET;ORAL	211550	ANDA	Accord Healthcare Inc.	16729-433-10	30 TABLET in 1 BOTTLE (16729-433-10)	2019-10-07
Alkem Labs Ltd	EZETIMIBE	ezetimibe	TABLET;ORAL	209234	ANDA	Major Pharmaceuticals	0904-7103-04	30 BLISTER PACK in 1 CARTON (0904-7103-04) / 1 TABLET in 1 BLISTER PACK	2017-12-23
Alkem Labs Ltd	EZETIMIBE	ezetimibe	TABLET;ORAL	209234	ANDA	Major Pharmaceuticals	0904-7103-10	20 BLISTER PACK in 1 CARTON (0904-7103-10) / 1 TABLET in 1 BLISTER PACK	2017-12-23
Alkem Labs Ltd	EZETIMIBE	ezetimibe	TABLET;ORAL	209234	ANDA	A-S Medication Solutions	50090-3657-0	30 TABLET in 1 BOTTLE, PLASTIC (50090-3657-0)	2017-12-23
Alkem Labs Ltd	EZETIMIBE	ezetimibe	TABLET;ORAL	209234	ANDA	A-S Medication Solutions	50090-3657-1	90 TABLET in 1 BOTTLE (50090-3657-1)	2017-12-23

Suppliers for the Pharmaceutical Drug: Ezetimibe

Last updated: August 1, 2025

Introduction

Ezetimibe, a cholesterol absorption inhibitor, is widely prescribed to lower low-density lipoprotein (LDL) cholesterol levels, often used in combination with statins or as monotherapy for hypercholesterolemia management. Its patent expiration and the subsequent rise in generic manufacturing have expanded the global supplier base. This article analyzes the key suppliers of ezetimibe, examining manufacturing dynamics, market share, regulatory considerations, and supply chain implications. Catering to industry professionals, it provides comprehensive intelligence to inform procurement, strategic planning, and risk management.

Market Overview of Ezetimibe Suppliers

Since its approval by the U.S. Food and Drug Administration (FDA) in 2002, ezetimibe has transitioned from a proprietary drug (Zetia, marketed by Merck & Co.) to a widely available generic. The generic market’s growth has introduced a diversified supplier ecosystem, with manufacturers spanning North America, Europe, and Asia.

Original Manufacturer and Patent Status

Merck’s proprietary ezetimibe (Zetia) dominated the early market. Its patent expiration in multiple regions around 2016-2017 allowed generic manufacturers to enter the market legally. Notably, patent exclusivity was challenged in various jurisdictions, leading to an influx of generics.

Emergence of Generics and Key Suppliers

The key suppliers of ezetimibe today include:

• Teva Pharmaceutical Industries Ltd. (Israel): A pioneer in generic pharmaceuticals, Teva was among the first to manufacture and distribute ezetimibe following patent expiration. Its extensive global network facilitates broad distribution.
• Mylan N.V. (now part of Viatris): A major player with significant manufacturing capacity, Mylan has been a competitive supplier of ezetimibe.
• Sandoz (Novartis): Sandoz offers generic ezetimibe with robust regulatory approvals, especially in European markets.
• Dr. Reddy's Laboratories (India): Prominent in Asia, Dr. Reddy’s supplies ezetimibe formulations and active pharmaceutical ingredients (APIs).
• Sun Pharmaceutical Industries (India): One of India’s leading generics manufacturers, Sun Pharma supplies ezetimibe through both APIs and finished doses.
• Macleods Pharmaceuticals (India): A key supplier of ezetimibe API, serving regional and global markets.
• Zydus Cadila (India): Active in manufacturing ezetimibe formulations and APIs.
• Lupin Limited (India): Supplies both ezetimibe API and formulations within Asia and beyond.
• Aurobindo Pharma (India): A significant participant with a focus on API production.

API Production and Formulation

Given the importance of supply chain security, several manufacturers focus primarily on the API, which is then supplied globally to finished dosage manufacturers. India’s pharmaceutical industry has become a global hub for API production, with companies such as Aurobindo, Sun Pharma, and Macleods leading the segment.

Key API Manufacturers include:

• Macleods Pharmaceuticals
• Aurobindo Pharma
• Hetero Drugs
• Zhejiang Hisun Pharmaceuticals (China): Expanding API capacity to serve international markets.

Finished Dose Manufacturers:

Most original and generic companies produce ezetimibe tablets, often in combination with simvastatin or atorvastatin, reflecting prescribing patterns.

Supply Chain and Regulatory Considerations

The supply of ezetimibe hinges substantially on regulatory approval processes in key markets such as the U.S., Europe, and emerging markets in Asia and Latin America. Regulatory harmonization efforts and quality standards influence supplier choices.

• Quality Compliance: Manufacturers must adhere to Good Manufacturing Practices (GMP) per agencies like the FDA and EMA.
• Regulatory Approvals: Securing ANDA (Abbreviated New Drug Application) in the U.S. or equivalence certificates in Europe impacts manufacturing and supply continuity.
• Supply Chain Disruptions: Political, logistical, or pandemic-related disruptions can impede supply, especially for API producers in regions with less resilient infrastructure.

Market Dynamics and Competitive Landscape

The ezetimibe market is characterized by:

• Price Competition: The entry of multiple generics has driven prices downward. Suppliers compete primarily on cost-efficiency and quality.
• Patent Challenges: Ongoing patent disputes influence market share; for example, generic suppliers have litigated patent protections in various countries.
• Partnerships and Licensing: Collaborative agreements between brand owners and generics have occasionally refined supply arrangements and patent licensing.

Emerging Trends and Future Outlook

Key trends shape the procurement strategy for ezetimibe suppliers:

• Vertical Integration: Some large generic manufacturers integrate API production and finished dose manufacturing to secure supply.
• Regional Expansion: API manufacturing capacities are expanding in China and India to meet growing global demand.
• Regulatory Stringency: Increased quality standards and approvals for biosimilar and generic drugs may influence supplier choices.
• Sustainability: Manufacturers are adopting environmentally sustainable practices, influencing supplier selection.

Supply Risks and Risk Mitigation

Supply chain risks include geopolitical tensions, export restrictions, quality issues, and raw material shortages.

Risk mitigation strategies:

• Diversification of supplier base across geographies.
• Building strategic stockpiles of APIs and finished doses.
• Engaging in long-term supply agreements with multiple manufacturers.
• Monitoring regulatory developments closely.

Conclusion

The supply landscape for ezetimibe has matured post-patent expiry, with India and China emerging as predominant API hubs. Leading global suppliers, notably Teva, Mylan/Viatris, and Sandoz, dominate finished dose markets, while API manufacturing remains concentrated among regional giants such as Macleods and Aurobindo. Ensuring consistent supply requires careful evaluation of regulatory compliance, quality standards, and geopolitical stability. Companies seeking to secure ezetimibe supplies must adopt diversified sourcing strategies aligned with evolving market dynamics.

Key Takeaways

• Diverse Supplier Ecosystem: The ezetimibe market includes a broad spectrum of suppliers, primarily from India, China, and established Western generic firms.
• API and Formulation Segmentation: API manufacturers focus on raw ingredient supply, whereas finished dose producers manage formulation and distribution.
• Regulatory & Quality Mandates: Compliance with GMP and regulatory approvals are critical for uninterrupted supply.
• Supply Chain Risks: Geopolitical, logistical, and quality issues pose risks; diversification remains essential.
• Emerging Regional Capacity: Expanding manufacturing capacities in emerging markets are expected to influence supply stability and pricing.

FAQs

1. Who are the leading manufacturers of ezetimibe API?
India-based companies such as Aurobindo Pharma, Macleods Pharmaceuticals, and Sun Pharma dominate API production, with Chinese manufacturers like Zhejiang Hisun Pharmaceuticals expanding capacity.

2. Can generic ezetimibe be considered as effective as the brand-name version?
Yes. Generic ezetimibe undergoes rigorous bioequivalence testing and regulatory scrutiny, ensuring comparable efficacy and safety to the brand-name product.

3. How does patent status affect ezetimibe supply?
Patent expiration has enabled numerous generics to manufacture ezetimibe, increasing supply and reducing prices. Ongoing patent disputes may temporarily restrict certain suppliers.

4. What are the main risks in sourcing ezetimibe?
Key risks include regulatory hurdles, supply disruptions due to geopolitical issues, raw material shortages, and quality inconsistencies across suppliers.

5. How is the supply of ezetimibe expected to evolve?
Expansion in API manufacturing capacity, ongoing market competition, and regulatory harmonization suggest a stable, diversified supply landscape with competitive pricing.

---

Sources
[1] U.S. Food and Drug Administration (FDA). Ezetimibe Approval History.
[2] IQVIA Institute. The Changing Landscape of Cardiovascular Therapies.
[3] GlobalData Pharma Intelligence Center. Ezetimibe Market Analysis.
[4] European Medicines Agency (EMA). Regulatory Approvals for Ezetimibe.
[5] Pharmaceutical Technology. API Manufacturing Trends in India and China.